Up-regulation of pS2 expression during the development of adenocarcinomas but not squamous cell carcinomas of the uterine cervix, independently of expression of c-jun or oestrogen and progesterone receptors

Journal of Pathology

Volumn 190, Issue 5, 2000, Pages 554-563

  Saegusa, Makoto ^a   Hashimura, Miki ^a   Hara, Atsuko ^a   Okayasu, Isao ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

c jun; ER ; ER ; PR; pS2; Uterine cervical neoplasms

Indexed keywords

ESTROGEN RECEPTOR; GENE PRODUCT; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN C JUN; PROTEIN PS2;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; ONCOGENE C JUN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 0034024525     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200004)190:5<554::AID-PATH557>3.0.CO;2-V     Document Type: Article

References (38)

1. Ferenczy A, Winkler B. Anatomy and histology of the cervix. Blaustein's Pathology of the Female Genital Tract, Kurman RJ (ed). Springer-Verlag: New York, 1987; 141-157.
2. Umayahara Y, Kawamori R, Watada H, et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994; 269: 16433-16442.
3. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-5930.
4. Tremblay GB, Tremblay A, Copeland NG, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol Endocrinol 1997; 11: 353-365.
5. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
6. Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-870.
7. Wright NA, Hoffmann W, Otto WR, Rio MC, Thim L. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett 1997; 408: 121-123.
8. Playford RJ, Marchbank T, Goodlad RA, et al. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 1996; 93: 2137-2142.
9. Masiakowski P, Breathnach R, Bloch I, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982; 10: 7895-7903.
10. Rio MC, Bellocq JP, Gairard B. et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene erbB2. Proc Natl Acad Sci USA 1987; 84: 9243-9247.
11. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1994; 73: 2013-2026.
12. Saegusa M, Kamata Y, Isono M, Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 1996; 180: 275-282.
13. Leygue ER, Watson PH, Murphy LC. Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst 1996; 88: 284-290.
14. Carr M, May FEB, Lennard TWJ, Westley BR. Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction. Br J Cancer 1995; 72: 1427-1434.
15. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R. Expression of estrogen receptor β messenger RNA variant in breast cancer. Cancer Res 1998; 58: 210-214.
16. Pujol P, Rey J-M, Nirde P, et al. Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58: 5367-5373.
17. Saegusa M, Hashimura M, Hara A, Okayasu I. Loss of expression of the gene deleted in colon carcinoma (DCC) is closely related to histologic differentiation and lymph node metastasis in endometrial carcinoma. Cancer 1999; 85: 453-164.
18. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res 1999; 59: 529-5.32.
19. Brown AM, Jeltch JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 1984; 81: 6344-6348.
20. Hackel C, Falkenberg B, Gunther T, Lippert H, Roessner A. The pS2 protein in colorectal carcinomas and metastasis. Pathol Res Pract 1998; 194: 171-176.
21. Singh S, Poulson R, Hanby AM, et al. Expression of oestrogen receptor and oestrogen-inducible genes pS2 and ERD5 in large bowel mucosa and cancer. J Pathol 1998; 184: 153-160.
22. Luqmani YA, Campbell T, Soomro S, Shousha S, Rio MC, Coombes RC. Immunohistochemical localization of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer 1993; 67: 749-753.
23. Koshiyama M, Yoshida M, Konishi M, et al. Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status. Int J Cancer 1997; 74: 237-244.
24. Kuiper GGJM, Gustafsson J-A. The novel estrogen receptor-subtype: potential role in the cell- and promoter-specific actions of estrogen and anti-estrogens. FEBS Lett 1997; 410: 87-90.
25. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res 1998; 58: 3197-3201.
26. Fujiwara H, Tortolero-Luna G, Mitchell MF, Koulos JP, Wright TC Jr. Adenocarcinoma of the cervix: expression and clinical significance of estrogen and progesterone receptors. Cancer 1997; 79: 505-512.
27. Nonogaki H, Fujii S, Konishi I, et al. Estrogen receptor localizalion in normal and neoplastic epithelium of the uterine cervix. Cancer 1990; 66: 2620-2627.
28. Gillesby BE, Stanostefano M, Porter W, Safe S, Wu ZF, Zacharewski TR. Identification of a motif within the 5′ regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. Biochemistry 1997; 36: 6080-6089.
29. Gaub M-P, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos jun complex. Cell 1990; 63: 1267-1276.
30. Thompson AM, Elton RA, Hawkins RA, Chetty U, Steel CM. pS2mRNA expression adds prognostic information to node status for 6-year survival in breast cancer. Br J Cancer 1998; 77: 492-496.
31. Chaubert P, Bouzourene H, Saraga F. Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population. Mod Pathol 1996; 9: 189-193.
32. Speiser P, Mayerhofer K, Kucera E, et al. pS2 and PAI-1 in ovarian cancer: correlation to pathohistologic parameters. Anticancer Res 1997; 17: 679-683.
33. Fuqua SAW, Fitzgerald SD, Chamness G, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51: 105-109.
34. Castles CG, Fuqua SAW, Klotz DM, Hill SM. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993; 53: 5934-5939.
35. Ohlsson H, Lykkesfeldt AE, Madsen MW, Briand P. The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1. Cancer Res 1998; 58: 4264-4268.
36. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-α) and beta (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-β in neoplastic tissues. J Clin Endocrinol Metab 1998; 83: 1025-1028.
37. Hanby AM, Poulsom R, Singh S, Elia G, Jeffery RE, Wright NA. Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypetide and pS2 in the stomach. Gastroenterology 1993; 105: 1110-1116.
38. Labouvie C, Machado JC, Carneiro F, et al. Differential expression of mucins and trefoil peptides in native epithelium. Barrett's metaplasia and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 1999; 125: 71-76.